Apollo Peptide Sciences

Why we recommend Apollo Peptide Sciences

Apollo Peptide Sciences launched in 2024 and made an immediate strategic bet: specialize in GLP-1 peptides and compete on depth rather than breadth. Its core offering — Semaglutide, Tirzepatide, and Retatrutide — covers the three most-researched GLP-1 and dual-agonist compounds in the market, with HPLC-verified purity documentation. Testing score: 6.0 out of 7. Tier-1 US vendor. Discount code APOLLO10 gives 10% off. We evaluate Apollo against Pepticker's 7-criterion methodology (https://pepticker.com/methodology), and its combination of GLP-1 specialization and HPLC documentation earns it a recommended verdict despite the short track record.

Testing & COA practices

HPLC purity verification is documented across Apollo's GLP-1 catalog. The GLP-1 category has particular purity concerns: Semaglutide synthesis produces related impurities that HPLC can detect and quantify, making testing documentation directly relevant to research protocol validity. COA links were confirmed active as of our April 2026 verification. No mass-spec identity or additional panels are listed — the same single-panel limitation as most 6.0-scoring vendors in our registry. Under our methodology, single-panel HPLC satisfies the baseline testing criterion but does not earn the bonus points reserved for dual-panel or quad-panel programs.

Shipping, quality, and customer service

Domestic shipping is $8.95 flat — competitive for a tier-1 US vendor and below the median for GLP-1 specialists. Orders ship from the US. Customer service feedback is sparse in our dataset given Apollo's 2024 founding, but no pattern of unresolved disputes has emerged. For a GLP-1-focused vendor where Semaglutide and Tirzepatide orders frequently represent significant dollar values, the absence of negative customer service signal is a meaningful positive for a vendor this new.

Product range

The GLP-1 specialization is the headline. Semaglutide and Tirzepatide are the dominant research compounds in metabolic and obesity research; Retatrutide (a triple GIP/GLP-1/glucagon agonist) is a newer entrant that far fewer vendors stock. Apollo's depth in this category — multiple vial sizes, concentrations, and formulations — makes it the natural first choice for GLP-1-focused protocols. The GLP-1 specialization means the catalog is narrow — classic recovery peptides (BPC-157, TB-500) and longevity compounds are not the focus.

Where they fall short

Apollo was founded in 2024, giving it a shallow community track record compared to vendors with five-plus years of operations. Single-panel HPLC means no mass-spec identity confirmation. Researchers who need a one-stop shop should pair Apollo for GLP-1 purchases with a generalist vendor for other compounds. No international warehousing.

Bottom line

Apollo Peptide Sciences is the clearest recommendation for GLP-1-focused research: Semaglutide, Tirzepatide, and Retatrutide under HPLC verification, from a vendor that has staked its brand on this category. For anything outside GLP-1s, use a generalist. Review our full scoring criteria at https://pepticker.com/methodology. Use code APOLLO10.

Apollo Peptide Sciences is a 2024-launched, GLP-1–specialized research peptide vendor that focuses narrowly on Semaglutide, Tirzepatide, and Retatrutide. This specialization allows them to compete on depth (multiple vial sizes, concentrations, and formulations) rather than breadth, making them a strong choice for GLP-1–centric research protocols.

Evaluation summary

• Tier: Tier-1 US vendor
• Testing score: 6.0 / 7
• Discount code: APOLLO10 for 10% off
• Shipping: $8.95 domestic
• Last verified: 4 May 2026

Across seven criteria — operational status, testing methodology, COA verification, shipping, customer service, pricing, and longevity — Apollo scores particularly well on testing and COA for its focused GLP-1 catalog, is adequate on pricing and shipping, and is limited on longevity due to its 2024 founding.

Testing & COA practices

• HPLC purity verification is documented for all GLP-1 offerings.
• This is especially important for GLP-1 compounds like Semaglutide, where synthesis can generate related impurities that HPLC can detect and quantify.
• As of the 4 May 2026 verification, Apollo is operational with active COA access.
• Limitations:
  • No mass-spectrometry (MS) identity confirmation listed.
  • No additional testing panels beyond HPLC.
  • This places Apollo in line with most vendors that score around 6.0 on testing.
• Upgrade path: Adding at least mass-spec identity confirmation would be the most impactful single improvement to their testing profile.

Product range & pricing

• Core focus: GLP-1 and related incretin agonists.
  • Semaglutide – a leading compound in metabolic and obesity research.
  • Tirzepatide – a dual GIP/GLP-1 agonist with strong research interest.
  • Retatrutide – a newer triple agonist (GIP/GLP-1/glucagon) that relatively few vendors carry.
• Depth over breadth:
  • Multiple vial sizes and formulations within this GLP-1 family.
  • Well-suited for labs or researchers running GLP-1–focused protocols.
• Shipping: $8.95 domestic.
• Pricing: Competitive but not aggressively undercutting the market; overall adequate rather than ultra-budget.